Mariposa: Longer-Term Follow-Up Of Amivantamab & Lazertinib In Egfr-M Nsclc

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

MARIPOSA: follow-up of lazertinib with amivantamab or osimertinib in EGFR-m NSCLC

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLC

MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLC

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

MARIPOSA/MARIPOSA-2 ESMO 2024 - Importance of Amivantamab in mNSCLC Insights on Resistance Patterns

Oncology Brothers Clips

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

MARIPOSA Update - Amivantamab + Lazertinib in 1L EGFR mutated metastatic NSCLC.

OncBrothers: Practice-Changing Cancer Discussions

Dr. Gadgeel Discusses Updated MARIPOSA Results at IASLC 2024 World Conference on Lung Cancer

Lung Cancers Today

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander Spira

OncBrothers: Practice-Changing Cancer Discussions

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

European Society for Medical Oncology (ESMO)

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

PALOMA-3: utilization & patient satisfaction of subcutaneous amivantamab in NSCLC

COMBI-AD: long-term follow-up of dabrafenib and trametinib in BRAF-mutated melanoma